Valeant Pharmaceuticals International VRX
Valeant is a platform compounder that traditional P/E undervalues; SOTP plus credit for ongoing M&A implies $330+/share vs $223 today, with up to $618 by 2020.
Thesis
Pershing Square argues that Valeant Pharmaceuticals — a serial acquirer run by CEO Mike Pearson that has compounded ~4,500% since 2008 by buying bloated pharma assets, stripping R&D, and integrating them into a low-tax, decentralized platform — is structurally undervalued because traditional multiple-of-earnings valuation ignores the durable franchise mix and the embedded option to deploy future free cash flow into accretive deals. Using Jarden, Platform Specialty Products, Nomad Holdings, Danaher and Transdigm as proof that 'platform value' is real and recurring, Ackman builds a sum-of-parts model that values VRX's durable portfolio at 20x forward earnings and its patent-cliff portfolio via DCF, then layers in scenarios for $5-$20bn of annual M&A through 2020. Conclusion: at $223, fair value is $330+/share excluding pipeline upside, with 2020 value reaching $446-$618.
SCQA
Valeant is a $75bn pharma roll-up run by Mike Pearson that has delivered ~4,500% TSR since 2008 by acquiring traditional pharma assets, gutting R&D, and integrating them into a low-tax, decentralized operating platform.
The market values VRX on a single forward P/E (~14x 2016 EPS), which captures only the existing asset base and ignores 'Platform Value' — the predictable upside from continued accretive acquisitions funded by free cash flow and 4x leverage.
Reframe valuation as sum-of-parts: 20x forward earnings on the durable portfolio (per Perrigo, Zoetis, beauty/personal-care comps), DCF on the patent-cliff portfolio, and explicit credit for $5-$20bn of annual M&A through 2020.
At $223 today, fair value is $330+/share excluding pipeline; present value reaches $286-$396 (28-78% upside) under varying M&A scenarios, and 2020 value scales to $446-$618 per share.
The three reasons
- 1
Valeant compounded ~45x in seven years under Mike Pearson's acquire-and-integrate platform strategy
- 2
Has earned >20% unlevered IRR on $20bn+ of acquisitions; B&L deal alone created $12-15bn of value
- 3
Standard P/E ignores Platform Value; SOTP plus future M&A implies $330-$396 vs $223 today
Primary demands
- Investors should value Valeant using a sum-of-parts framework (20x for durable portfolio, DCF for patent-cliff portfolio) rather than a single blended P/E multiple
- Ascribe explicit 'Platform Value' to VRX for its proven ability to deploy free cash flow into accretive acquisitions
- Re-rate the stock toward $330+ per share, with upside to ~$400-$618 under aggressive M&A scenarios
KPIs cited
Pattern membership
Precedents cited
- Jarden Corporation under Martin Franklin (~45x over 14 years)
- Platform Specialty Products / PAH (Franklin + Berggruen, ~175% in 2 years)
- Nomad Holdings / Iglo Foods acquisition (Franklin + Gottesman, ~80% since IPO)
- Danaher
- Liberty Media
- AB InBev
- TransDigm
- Valeant's Bausch & Lomb acquisition ($8.7bn in, $21bn+ out)
Composition what's on the 47 slides
Slide gallery ·
Notes
Bill Ackman's 2015 Ira Sohn keynote unveiling the Valeant long thesis. Argument is constructed by analogy: three opening case studies (Jarden, Platform Specialty Products, Nomad) establish 'platform value' as a recurring pattern, then Valeant is positioned as the under-appreciated pharma instance of the same template. Notable for the explicit SOTP framework (durable portfolio at 20x P/E vs patent-cliff portfolio via DCF) and the M&A-cap sensitivity table ($0/$5/$10/$20bn annual deployment). Famously a thesis that subsequently collapsed when Valeant's pricing/Philidor scandals broke later in 2015 — keep this deck as the canonical 'platform value' specimen and as a study in over-confidence in a serial-acquirer narrative. Tone is bullish/analytical, not adversarial — no villain, no CEO quote-traps. Production is standard Pershing Square house style (blue/grey, Arial, line charts with annotated callouts) — competent but not editorial-tier. Page numbering on cover is unusual ('45x' as the only image).